Cardiovascular Disease in Special Populations: From Basic Science to Clinical Practice

Topic Information

Dear Colleagues,

Research on cardiovascular diseases (CVDs) has experienced significant growth in recent years, increasing our understanding and fueling the discovery of prominent therapeutic options. Despite these advancements, there are still many unknowns regarding the manifestation and treatment of CVDs in special populations. Special populations can encompass a wide range of physical, sensory, cognitive, and metabolic factors, each influencing cardiovascular health differently. As such, there is a significantly greater health concern in special populations, as recent studies have found that factors specific to special populations contribute to heightened CVD risk factors and early mortality. In addition, it is unclear as to whether common CVD treatment options are effective in CVD patients from special populations. Therefore, the goal of this research topic is to provide a scientific platform that fosters our clinical understanding of the manifestation as well as the effectiveness of therapeutic interventions in special populations with CVD. Both research and review articles are welcome.

Dr. Song-Young Park
Dr. Gwenael Layec
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Antioxidants antioxidants	6.0	10.6	2012	15.5 Days	CHF 2900	Submit
Biomedicines biomedicines	3.9	5.2	2013	15.3 Days	CHF 2600	Submit
Disabilities disabilities	-	1.1	2021	39.9 Days	CHF 1000	Submit
Journal of Cardiovascular Development and Disease jcdd	2.4	2.6	2014	22.9 Days	CHF 2700	Submit

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

1. Immediately share your ideas ahead of publication and establish your research priority;
2. Protect your idea from being stolen with this time-stamped preprint article;
3. Enhance the exposure and impact of your research;
4. Receive feedback from your peers in advance;
5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Antioxidants Biomedicines Disabilities JCDD

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 582 KiB)

13 pages, 2706 KiB  

Open AccessArticle

Changes in Mitochondrial Function and Cell Death Patterns in Peripheral Blood Mononuclear Cells during Trastuzumab Treatment Following Doxorubicin Chemotherapy

by Krit Leemasawat, Nichanan Osataphan, Nattayaporn Apaijai, Panat Yanpiset, Arintaya Phrommintikul, Areewan Somwangprasert, Siriporn C. Chattipakorn and Nipon Chattipakorn

Biomedicines 2024, 12(9), 1970; https://doi.org/10.3390/biomedicines12091970 - 1 Sep 2024

Viewed by 263

Abstract

Trastuzumab, a monoclonal antibody which works against human epidermal growth factor receptor 2 (HER2), possibly causes cardiotoxicity through mitochondrial dysfunction. The usefulness of isolated peripheral blood mononuclear cells (PBMCs) in the assessment of trastuzumab-induced cardiotoxicity remains uncertain. This study aimed to determine the [...] Read more.

Trastuzumab, a monoclonal antibody which works against human epidermal growth factor receptor 2 (HER2), possibly causes cardiotoxicity through mitochondrial dysfunction. The usefulness of isolated peripheral blood mononuclear cells (PBMCs) in the assessment of trastuzumab-induced cardiotoxicity remains uncertain. This study aimed to determine the temporal changes in mitochondrial function, oxidative stress, and cell death in the isolated PBMCs of HER2-positive breast cancer patients during breast cancer treatment and to compare the changes with HER2-negative breast cancer patients who did not receive trastuzumab therapy. Eighteen newly diagnosed HER2-positive breast cancer women who received sequential doxorubicin and trastuzumab were consecutively recruited. Age- and gender-matched controls with HER2-negative breast cancer were selected. Echocardiography was carried out, and blood samples for the study of cardiac biomarkers and PBMCs were collected periodically during treatment. Only one patient in our cohort developed asymptomatic left ventricular dysfunction during trastuzumab treatment. However, trastuzumab following doxorubicin aggravated subclinical cardiac injury, determined by cardiac troponin and echocardiography. Cellular and mitochondrial oxidative stress in isolated PBMCs remained unchanged throughout breast cancer treatment. Regarding mitochondrial respiration, the maximal respiration and spare respiration capacity was significantly increased in controls after doxorubicin treatment but not in patients who received trastuzumab therapy. Moreover, the percentage of apoptosis and necroptosis in isolated PBMCs was dramatically decreased in the control, compared to patients with trastuzumab treatment. In conclusion, trastuzumab caused subtle myocardial injury and impaired mitochondrial respiration and cell viability in isolated PBMCs. Full article

(This article belongs to the Topic Cardiovascular Disease in Special Populations: From Basic Science to Clinical Practice)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1